About

Founded with the mission to address the challenges of bifurcation disease, Advanced Bifurcation Systems (ABS) has developed a Class III medical device that has received the FDA’s Breakthrough Device Designation. Our technology is designed to enable the minimally invasive treatment of cardiac bifurcation lesions, which are often deemed too complex for standard stenting procedures. Led by the Founders: Dr. Mehran J. Khorsandi (cardiologist, Cedars Sinai Medical Center) and Henry Bourang (renowned medical devices engineer), ABS is committed to improving patient outcomes by empowering more cardiologists to perform bifurcation stenting with greater safety and efficiency, and converting more patients from open-heart surgery to a minimally invasive stent procedure.

ABS’s device positions the company as a future leader in the global cardiology device market, with an addressable market of $5 billion. The device is protected by over 70 issued and 35 pending patents, domestically and internationally.

ABS has successfully raised $40 million to date and will be seeking a Series B Preferred financing in early 2025. FDA approval is targeted for late 2026.